Kinnate Zeroes In On BRAF Subpopulation For Exarafenib Development Strategy

BeiGene And Partners Present RAF Dimer Inhibitor Data

 
• By Alaric DeArment
  
Kinnate presented Phase I data for its pan-RAF inhibitor, exarafenib • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category